You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
科興製藥(688136.SH):與蘇州東曜簽署貝伐珠單抗藥物海外市場獨家商業化許可合作協議
格隆匯 01-11 16:10

格隆匯1月11日丨科興製藥(688136.SH)公佈,公司於2022年1月11日與東曜藥業有限公司(“蘇州東曜”)簽署《貝伐珠單抗藥物海外市場獨家商業化許可合作協議》,授予公司就貝伐珠單抗藥物(“標的藥品”)在除中國、歐盟(以2021年歐盟成員國為準)、英國、美國、日本以外全球所有國家和地區(“合作區域”)獨家商業化許可。

科興製藥支付蘇州東曜首付款及研發里程碑款總金額為3000萬元人民幣,其中首付款1000萬元人民幣。科興製藥根據標的藥品在所有合作區域內累計淨銷售額支付蘇州東曜銷售里程碑款及銷售提成,可能支付的最大銷售里程碑款為3.8億元人民幣,銷售提成百分比為兩位數至高個位數。銷售里程碑款及銷售提成最終付款金額尚存在一定的不確定性。

標的產品已於2021年11月30日在中國大陸地區獲批上市,在雙方合作區域內的國家和地區均未提交上市申請。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account